Clinical trials: Glaucoma Diagnosis
Glaucoma
12-Month Stability of Diurnal IOP Control on Cosopt
To determine the stability of diurnal intraocular pressure in eyes with glaucoma treated with Cosopt
- Trial name
- NCT00379834
- Testing
- Cosopt
- Volunteers
- 10 people
- Sponsor
- West Virginia University
Glaucoma
Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on Brimonidine 0.2%/Timolol 0.5% Fixed Combination Therapy (COMBIGAN®) in Latin America
The purpose of this study was to assess the efficacy and tolerability of changing to AZARGA® from prior COMBIGAN® pharmacotherapy in participants with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT01518244
- Testing
- Brinzolamide/timolol maleate fixed combination
- Volunteers
- 50 people
- Sponsor
- Alcon Research
Primary Open Angle Glaucoma
Safety and Performance of Miami InnFocus Drainage Implant (MIDI Arrow) Glaucoma Drainage Implant
To assess the safety and performance of the MIDI Arrow in patients suffering from glaucoma that is inadequately controlled on maximum tolerated medical therapy with intraocular pressure ≥ 18 mm Hg and ≤ 40 mm Hg
- Trial name
- NCT01563237
- Testing
- MIDI Arrow
- Where
- France
- Volunteers
- 69 people
- Sponsor
- InnFocus Inc.
Ocular Hypertension, Primary Open-Angle Glaucoma
Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
This study has 2 parts. Part 1 will evaluate the safety and IOP effects of 6 formulations of AGN-210961 ophthalmic solution in the study eye and bimatoprost ophthalmic solution 0.03% in the fellow eye for 7 consecutive days.
- Trial name
- NCT01110499
- Testing
- AGN-210961 Formulation 1, AGN-210961 Formulation 2, AGN-210961 Formulation 3
- Where
- United States
- Volunteers
- 163 people
- Sponsor
- Allergan
Glaucoma
The Effects of the Water Drinking Test on Intraocular Pressure
This clinical trial is designed to investigate the efficacy profile of the SENSIMED Triggerfish® during 24-hour IOP monitoring in patients with glaucoma or ocular hypertension, done three times at monthly intervals under…
- Trial name
- NCT01507584
- Testing
- SENSIMED Triggerfish
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of California, San Diego
Open-Angle Glaucoma, Ocular Hypertension
Patient Preference Comparison of AZARGA Versus COSOPT
The purpose of this study was to assess patient preference regarding ocular comfort of AZARGA® compared to COSOPT® after one week instillation of each study medication.
- Trial name
- NCT01340014
- Testing
- Brinzolamide 1.0% + Timolol 0.5% ophthalmic suspension, Dorzolamide 2.0% + Timolol 0.5% ophthalmic solution
- Volunteers
- 112 people
- Sponsor
- Alcon Research
Glaucoma, Neovascular
Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients
To assess the efficacy and safety of the administration of aflibercept by intravitreal injection in comparison to sham to control intraocular pressure in patients with neovascular glaucoma.
- Trial name
- VEGA (NCT02396316)
- Testing
- Aflibercept (Eylea, BAY 86-5321)
- Where
- 19 sites in Japan
- Volunteers
- 54 people
- Sponsor
- Bayer
Glaucoma, Ocular Hypertension
Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily (TID)
To compare Combigan Two Times Daily (BID) vs Simbrinza Three Times Daily (TID) in subjects currently being treated with Latanoprost for Open-Angle Glaucoma or Ocular Hypertension.
- Trial name
- NCT02167035
- Testing
- Combigan Two Times Daily (BID), Simbrinza Three Times Daily (TID)
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Cornerstone Health Care, PA
Glaucoma, Ocular Hypertension
Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
This study will evaluate the safety and efficacy of bimatoprost/timolol formulation A ophthalmic solution with Ganfort® (bimatoprost 0.03%/timolol 0.5% ophthalmic solution) once daily for 12 weeks in patients with glaucoma or…
- Trial name
- NCT01177098
- Testing
- bimatoprost /timolol formulation A fixed combination ophthalmic solution, bimatoprost/timolol fixed combination ophthalmic solution
- Where
- 9 sites in United States, Australia and 7 more
- Volunteers
- 561 people
- Sponsor
- Allergan
Primary Open-Angle Glaucoma, Ocular Hypertension
An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert
This study evaluated the long-term (9-months) safety of the Bimatoprost Ocular Insert in participants with Glaucoma or Ocular Hypertension who completed study FSV5-004.
- Trial name
- OLE2 (NCT02537015)
- Testing
- Bimatoprost
- Where
- 9 sites in United States
- Volunteers
- 81 people
- Sponsor
- ForSight Vision5, Inc.
Glaucoma
Steroids After Laser Trabeculoplasty for Glaucoma
The purpose of this study is to determine whether the choice of post-operative eye drop administered after selective laser trabeculoplasty (SLT) for glaucoma affects the efficacy in lowering intraocular pressure (IOP).
- Trial name
- SALT (NCT00981435)
- Testing
- Prednisolone 1%, Ketorolac, Artificial Tears
- Where
- 2 sites in United States
- Volunteers
- 97 people
- Sponsor
- Stanford University
Glaucoma, Ocular Hypertension
6-Week Proof-of-Concept Study of Travoprost/Brinzolamide Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular Hypertension
The purpose of this study is to evaluate Travoprost/Brinzolamide fixed combination (Trav/Brinz) administered twice daily as compared to each of its marketed components (TRAVATAN Z® solution and AZOPT® suspension) and to the…
- Trial name
- NCT02140060
- Testing
- Dose Level A / Brinzolamide 1% ophthalmic suspension, Dose Level B / Brinzolamide 1% ophthalmic suspension, Dose Level C / Brinzolamide 1% ophthalmic suspension
- Volunteers
- 327 people
- Sponsor
- Alcon Research
Glaucoma
Tolerability of Bimatoprost 0.01% vs Latanoprost Eye Drops
This study examines patient perceptions regarding the tolerability of two classes of glaucoma medication: bimatoprost and latanoprost.
- Trial name
- NCT02138461
- Where
- United States
- Volunteers
- 211 people
- Sponsor
- MDbackline, LLC
Open Angle Glaucoma, Ocular Hypertension
180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma
Selective laser trabeculoplasty (SLT) is a well-recognized way to lower eye pressure in treatment of glaucoma. This treatment is performed for 180 degrees or 360 degrees, and studies at academic centers have shown mixed results…
- Conditions
- Open Angle Glaucoma, Ocular Hypertension, Glaucoma, Open Angle, Pseudo-exfoliative, Pigment Dispersion Syndrome
- Trial name
- NCT02628223
- Testing
- Selective Laser Trabeculoplasty, Neodymium:Yttrium Aluminum Garnet (YAG) laser
- Where
- 2 sites in United States
- Volunteers
- 76 people
- Sponsor
- Temple University
Glaucoma
Effect of Myocilin Genetic Variants on Intraocular Pressure and Pressure Variation in Sitting and Supine Positions
The purpose of this study is to determine if one of the genes that can cause glaucoma, called myocilin, are associated with larger eye pressure and blood pressure changes in sitting and lying down positions without glaucoma drug…
- Trial name
- Myoc Gene (NCT00906087)
- Testing
- Cosopt (combination eyedrop of dorzolamide and timolol)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Michigan
Glaucoma
Trusopt and Cosopt; Ocular Perfusion Pressure and Blood Flow: New Long-term Prospective Data
To analyze Cosopt® in terms of its effects on ocular perfusion pressure and comprehensive ocular blood flow and in relation to visual field progression and optic nerve structural changes in an ongoing 3 year prospective study…
- Trial name
- NCT01145898
- Testing
- (Cosopt®, prostaglandin)
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Indiana University
Open-angle Glaucoma, Ocular Hypertension
24-hour IOP-lowering Effect of Brimonidine 0.1%
This study will evaluate the efficacy and safety of brimonidine 0.1% three-times daily in patients with glaucoma or ocular hypertension
- Trial name
- NCT00457795
- Testing
- brimonidine 0.1% (Alphagan® P)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Allergan
Glaucoma
MK0507A Clinical Study in Patients With Glaucoma and Ocular Hypertension (0507A-149)(COMPLETED)
The clinical study compares safety and efficacy of MK0507A (dorzolamide 1.0% / timolol 0.5%) with 1) timolol 0.5% and with 2) concomitant therapy with dorzolamide 1.0% / timolol 0.5% in patients with glaucoma and ocular…
- Trial name
- NCT00449956
- Testing
- dorzolamide hydrochloride (+) timolol maleate, Comparator: timolol maleate, Comparator: dorzolamide hydrochloride
- Volunteers
- 474 people
- Sponsor
- Merck Sharp & Dohme LLC
Glaucoma, Open-Angle, Ocular Hypertension
Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting
To evaluate the IOP lowering efficacy of netarsudil ophthalmic solution 0.02% when used as monotherapy or when used concomitantly with other IOP-lowering agents in subjects with elevated IOP due to open angle glaucoma or ocular…
- Trial name
- NCT03808688
- Testing
- Netarsudil Ophthalmic Solution 0.02%
- Where
- 22 sites in United States
- Volunteers
- 261 people
- Sponsor
- Aerie Pharmaceuticals
Intraocular Pressure, Glaucoma
24-hour IOP-lowering Effect of 0.01% Bimatoprost
This study will evaluate the 24-hour IOP-lowering efficacy of 0.01% bimatoprost once daily in patients with glaucoma or ocular hypertension
- Conditions
- Intraocular Pressure, Glaucoma, Ocular Hypertension
- Trial name
- NCT01271686
- Testing
- 0.01% bimatoprost
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of California, San Diego